Novartis' (NOVN SW/NVS) Ianalumab receives FDA breakthrough therapy designation for Sjögren’s disease and plans global submission in early 2026
Importance
Level 1
#SWITZERLAND#NOVARTIS AG#FDA#EQUITIES#EU SESSION#US SESSION#PHARMACEUTICALS#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#SWISS MARKET INDEX#NOVN#GLOBAL EQUITIES